Duration of smoking cessation is negatively associated with the magnitude of chronic prostatic inflammation and storage dysfunction in patients with benign prostatic hyperplasia.
chronic prostatic inflammation
duration of smoking
lower urinary tract symptoms
smoking cessation
urodynamic study
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
08
04
2020
accepted:
15
06
2020
pubmed:
28
7
2020
medline:
28
4
2021
entrez:
26
7
2020
Statut:
ppublish
Résumé
To evaluate the impact of smoking and the benefit of smoking cessation on lower urinary tract function and prostatic inflammation in patients with benign prostatic hyperplasia. The medical records of 118 benign prostatic hyperplasia patients who underwent transurethral prostatic surgery between 2006 and 2016 were analyzed. Their smoking history was confirmed. The relationship between smoking and main clinical parameters, International Prostate Symptom Scores, uroflowmetry, pressure flow study, magnitude of prostatic inflammation and the level of serum C-reactive protein was investigated. Furthermore, the relationships between smoking cessation and these clinical parameters were assessed. The International Prostate Symptom Scores for straining among the non-smokers were significantly lower than those of the smokers (1.71 vs 2.60, P = 0.029). In the pressure flow study, there were negative correlations between the duration of smoking and strong desire to void (correlation coefficient -0.314, P = 0.013), urgency (correlation coefficient -0.349, P = 0.008) and bladder volume at initial detrusor overactivity (correlation coefficient -0.417, P = 0.021). The duration of smoking cessation was negatively correlated with the magnitude of chronic prostatic inflammation (correlation coefficient -0.253, P = 0.027). In the pressure flow study, the duration of smoking cessation was positively correlated with urgency (correlation coefficient 0.286, P = 0.030) and maximum cystometric capacity (correlation coefficient 0.241, P = 0.050). Smoking could be a risk factor for the exacerbation of storage dysfunction in benign prostatic hyperplasia patients. Smoking cessation is effective in improving chronic prostatic inflammation and storage dysfunction.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
874-881Informations de copyright
© 2020 The Japanese Urological Association.
Références
Jha P. Avoidable global cancer deaths and total deaths from smoking. Nat. Rev. Cancer 2009; 9: 655-64.
Benowitz NL, Burbank AD. Cardiovascular toxicity of nicotine: Implications for electronic cigarette use. Trends Cardiovasc. Med. 2016; 26: 515-23.
US Department of Health and Human Services. The health consequences of smoking-50 years of progress: A report of the Surgeon General. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA, 2014.
van Berlo JH, Maillet M, Molkentin JD. Signaling effectors underlying pathologic growth and remodeling of the heart. J. Clin. Invest. 2013; 123: 37-45.
Liu Y, Pleasants RA, Croft JB et al. Smoking duration, respiratory symptoms, and COPD in adults aged ≥45 years with a smoking history. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10: 1409-16.
Jha P, Ramasundarahettige C, Landsman V et al. 21st-century hazards of smoking and benefits of cessation in the United States. N. Engl. J. Med. 2013; 368: 341-50.
Wu Y, Song P, Zhang W et al. Activation of AMPKα2 in adipocytes is essential for nicotine-induced insulin resistance in vivo. Nat. Med. 2015; 21: 373-82.
Warren GW, Sobus S, Gritz ER. The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support. Lancet Oncol. 2014; 15: e568-e580.
Yoshimura K, Terada N, Matsui Y, Terai A, Kinukawa N, Arai Y. Prevalence of and risk factors for nocturia: analysis of a health screening program. Int. J. Urol. 2004; 11: 282-7.
Bing MH, Moller LA, Jennum P, Mortensen S, Lose G. Nocturia and associated morbidity in a Danish population of men and women aged 60-80 years. BJU Int. 2008; 102: 808-14.
Kang D, Andriole GL, Van De Vooren RC et al. Risk behaviours and benign prostatic hyperplasia. BJU Int. 2004; 93: 1241-5.
Platz EA, Rimm EB, Kawachi I et al. Alcohol consumption, cigarette smoking, and risk of benign prostatic hyperplasia. Am. J. Epidemiol. 1999; 149: 106-15.
Maserejian NN, Kupelian V, Miyasato G, McVary KT, McKinlay JB. Are physical activity, smoking and alcohol consumption associated with lower urinary tract symptoms in men or women? Results from a population based observational study. J. Urol. 2012; 188: 490-5.
De Nunzio C, Brassetti A, Proietti F, Deroma M, Esperto F, Tubaro A. Metabolic syndrome and smoking are associated with an increased risk of nocturia in male patients with benign prostatic enlargement. Prostate Cancer Prostatic Dis. 2018; 21: 287-92.
Fichtenberg CM, Glantz SA. Association of the California tobacco control program with declines in cigarette consumption and mortality from heart disease. N. Engl. J. Med. 2000; 343: 1772-7.
Koskimäki J, Hakama M, Huhtala H, Tammela TL. Association of smoking with lower urinary tract symptoms. J. Urol. 1998; 159: 1580-2.
Brinkman GL, Coates EO Jr. The effect of bronchitis, smoking, and occupation on ventilation. Am. Rev. Respir. Dis. 1963; 87: 684-963.
Inamura S, Shinagawa T, Hoshino H et al. Appearance of high endothelial venule-like vessels in benign prostatic hyperplasia is associated with lower urinary tract symptoms. Prostate 2017; 77: 794-802.
Messner B, Bernhard D. Smoking and cardiovascular disease mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2014; 34: 509-15.
Csordas A, Bernhard D. The biology behind the atherothrombotic effects of cigarette smoke. Nat. Rev Cardiol. 2013; 10: 219-30.
Barua RS, Ambrose JA. Mechanisms of coronary thrombosis in cigarette smoke exposure. Arterioscler. Thromb. Vasc. Biol. 2013; 33: 1460-7.
Brook RD, Rajagopalan S, Pope CAet al.; American Heart Association Council on Epidemiology and Prevention, Council on the Kidney in Cardiovascular Disease, and Council on Nutrition, Physical Activity and Metabolism. Particulate matter air pollution and cardiovascular disease an update to the scientific statement from the American Heart Association. Circulation 2010; 121: 2331-78.
Kupelian V, Rosen RC, Roehrborn CG, Tyagi P, Chancellor MB, McKinlay JB. Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey. BJU Int. 2012; 110: 401-7.
Masuda H, Kihara K, Saito K et al. Reactive oxygen species mediate detrusor overactivity via sensitization of afferent pathway in the bladder of anaesthetized rats. BJU Int. 2008; 101: 775-80.
Zarifpour M, Nomiya M, Sawada N, Andersson KE. Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia. Prostate 2015; 75: 233-41.
Nomiya M, Andersson KE, Yamaguchi O. Chronic bladder ischemia and oxidative stress: new pharmacotherapeutic targets for lower urinary tract symptoms. Int. J. Urol. 2015; 22: 40-6.
Inamura S, Ito H, Shinagawa T et al. Serum C-reactive protein level is not associated with prostatic inflammation but with overactive detrusor in patients with benign prostatic hyperplasia. Neurourol. Urodyn. 2019; 38: 1728-36.
Ficarra V, Rossanese M, Zazzara M et al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr. Urol. Rep. 2014; 15: 463.
Wolf PA, D’Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA 1988; 259: 1025-9.